Citations (112)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Billy J. Molloy, Adam King, Lauren G. Mullin, Lee A. Gethings, Robert Riley, Robert S. Plumb & Ian D. Wilson. (2021) Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. Xenobiotica 51:4, pages 434-446.
Read now
Read now
Zi-Yi Xu & Jun-Ling Li. (2019) Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. OncoTargets and Therapy 12, pages 5467-5484.
Read now
Read now
Ping Fang, Xiang Zheng, Jiayang He, Honglei Ge, Pengfei Tang, Jianping Cai & Guoxin Hu. (2017) Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro. Drug Design, Development and Therapy 11, pages 1283-1290.
Read now
Read now
Antonio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, Assunta Sgambato, Francesca Casaluce, Giovanni Palazzolo, Paolo Maione & Cesare Gridelli. (2017) Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. Expert Opinion on Pharmacotherapy 18:2, pages 151-163.
Read now
Read now
Petra Martin, Scott P Owen & Natasha B Leighl. (2013) Gefitinib: Re-Emerging from the Shadows. Lung Cancer Management 2:5, pages 423-437.
Read now
Read now
Carmela Fimognari, Lorenzo Ferruzzi, Eleonora Turrini, Giovanni Carulli, Monia Lenzi, Patrizia Hrelia & Giorgio Cantelli-Forti. (2012) Metabolic and toxicological considerations of botanicals in anticancer therapy. Expert Opinion on Drug Metabolism & Toxicology 8:7, pages 819-832.
Read now
Read now
Derek R Duckett & Michael D Cameron. (2010) Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1175-1193.
Read now
Read now
M Tiseo, M Bartolotti, F Gelsomino & P Bordi. (2010) Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). Drug Design, Development and Therapy 4, pages 81-98.
Read now
Read now
Lynn Campbell, Fiona Blackhall & Nicholas Thatcher. (2010) Gefitinib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 11:8, pages 1343-1357.
Read now
Read now
Toyoaki Hida, Shizu Ogawa, Jang Chul Park, Ji Young Park, Junichi Shimizu, Yoshitsugu Horio & Kimihide Yoshida. (2009) Gefitinib for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:1, pages 17-35.
Read now
Read now
Articles from other publishers (102)
Guizhen Zhu, Yaoyao Zhao, Wenmei Zhang, Yuanyuan Wu, Yuanxing Liu, Guangsheng Guo, Xiayan Wang & Zhihong Liu. (2024) Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells. Chinese Chemical Letters 35:2, pages 108466.
Crossref
Crossref
Javad Malakootikhah, Mohammad Yahyaei, Reza Ghafarzadegan & Rezvan Ghafarzadegan. (2023) Herbal nano-formulations in lung cancer: Superiorities to original forms. Journal of Medicinal Plants 22:87, pages 1-25.
Crossref
Crossref
Yasuhito Fujisaka, Takatoshi Nakagawa, Kiichiro Tomoda, Marina Watanabe, Ninso Matsunaga, Yosuke Tamura, Soichiro Ikeda, Akihisa Imagawa & Michio Asahi. (2023) The cytotoxicity of gefitinib on patient‑derived induced pluripotent stem cells reflects gefitinib‑induced liver injury in the clinical setting. Oncology Letters 26:6.
Crossref
Crossref
Fengling Wang, Xue Zhang, Yanyan Wang, Yunna Chen, Huiyu Lu, Xiangyun Meng, Xi Ye & Weidong Chen. (2023) Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy. Drug Metabolism and Disposition 51:5, pages 543-559.
Crossref
Crossref
Rameshwar S. Cheke, Pritam Bagwe, Shubham Bhange & Prashant S. Kharkar. 2023. Medicinal Chemistry of Chemotherapeutic Agents. Medicinal Chemistry of Chemotherapeutic Agents
615
646
.
Hirofumi Nagai, Tsutomu Shimada, Yoshimitsu Takahashi, Mikako Nishikawa, Hiroyuki Tozuka, Yasuto Yamamoto, Osamu Niwa, Yutaka Takahara, Arimi Fujita, Katsuhiko Nagase, Kazuo Kasahara, Seiji Yano & Yoshimichi Sai. (2022) Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study. Journal of Pharmaceutical Health Care and Sciences 8:1.
Crossref
Crossref
Youhao Chen, Shaoxing Guan, Yanping Guan, Siyuan Tang, Yanying Zhou, Xueding Wang, Huichang Bi & Min Huang. (2022) Novel Clinical Biomarkers for Drug-Induced Liver Injury. Drug Metabolism and Disposition 50:5, pages 671-684.
Crossref
Crossref
Jill Kolesar, Spencer Peh, Levin Thomas, Gayathri Baburaj, Nayonika Mukherjee, Raveena Kantamneni, Shirley Lewis, Ananth Pai, Karthik S. Udupa, Naveena Kumar AN, Vivek M. Rangnekar & Mahadev Rao. (2022) Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Molecular Cancer 21:1.
Crossref
Crossref
Mingming Han, Xiaodan Zhang, Zhize Ye, Jing Wang, Qihui Kong, Xiaoqin Hu, Jianchang Qian, Jianping Cai & Guoxin Hu. (2021) Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib. Chemical Research in Toxicology 35:2, pages 265-274.
Crossref
Crossref
Xiao Shen, Guorong Fan, Gaolin Liu, Fan Wang, Qi Li, Xinyan Liu, Hong Zhu, Ying Zhu, Jiguang Lu & Shuowen Wang. (2021) Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report. Anti-Cancer Drugs 33:1, pages e802-e807.
Crossref
Crossref
Thu-Lan T. Luong, Chelsea N. Powers, Brian J. Reinhardt & Peter J. Weina. (2022) Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. Current Research in Pharmacology and Drug Discovery 3, pages 100112.
Crossref
Crossref
Mohammed A. S. Abourehab, Alaa M. Alqahtani, Bahaa G. M. Youssif & Ahmed M. Gouda. (2021) Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Molecules 26:21, pages 6677.
Crossref
Crossref
Billy Molloy, Lauren Mullin, Adam King, Lee A. Gethings, Robert S. Plumb & Ian D. Wilson. (2021) The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC–IM–MS Study. Metabolites 11:6, pages 379.
Crossref
Crossref
Yasushi Yamazoe & Masahiro Tohkin. (2021) Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template. Drug Metabolism and Pharmacokinetics 38, pages 100357.
Crossref
Crossref
Thu-Lan T. Luong, Michael J. McAnulty, David L. Evers, Brian J. Reinhardt & Peter J. Weina. (2021) Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan. Current Research in Toxicology 2, pages 217-224.
Crossref
Crossref
Chenxiang Wang, Lili Ying, Mi Jin, Fangfang Zhang, Dawei Shi, Ying Dai & Ziye Zhou. (2020) An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib. Cancer Chemotherapy and Pharmacology 87:1, pages 43-52.
Crossref
Crossref
Sho Sakamoto, Kazuhiro Sato, Yuri Takita, Yuka Izumiya, Naho Kumagai, Kazuhisa Sudo, Yukiyasu Hasegawa, Hayato Yokota, Yumiko Akamine, Yuji Okuda, Mariko Asano, Masahide Takeda, Masaaki Sano, Masatomo Miura & Katsutoshi Nakayama. (2020) ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. Investigational New Drugs 38:6, pages 1687-1695.
Crossref
Crossref
Zirui Wan, Lifang Guo, Pengfei Li, Zhixia Zhao, Benshan Xu, Lulu Ren, Yan Yan, He Liu, Yiwen Zhang & Lihong Liu. (2020) Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters. Journal of Clinical Pharmacy and Therapeutics 45:5, pages 1159-1167.
Crossref
Crossref
Chao Wang, Jingui Zhang, Simin Zhou, Limei Yu, Fangxuan Han, Ren Ling & Jin Ling. (2020) Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry. PLOS ONE 15:7, pages e0236523.
Crossref
Crossref
Can Zhao, Huifeng Hao, Haiyu Zhao, Wei Ren, Yanna Jiao, Guo An, Hong Sun, Shuyan Han & Pingping Li. (2020) Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity. Journal of Ethnopharmacology 255, pages 112770.
Crossref
Crossref
Chris Labaki, Elsa Rawadi, Roy Chebel, Ziad Bakouny, Jean-Pierre Droz & Joseph G. Kattan. (2020) Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review. Critical Reviews in Oncology/Hematology 150, pages 102947.
Crossref
Crossref
Shingo Oda, Nanaka Miyazaki, Koichi Tsuneyama & Tsuyoshi Yokoi. (2020) Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice. The Journal of Toxicological Sciences 45:8, pages 493-502.
Crossref
Crossref
Marie‐Noëlle Paludetto, Florent Puisset, Etienne Chatelut & Cécile Arellano. (2019) Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. Medicinal Research Reviews 39:6, pages 2105-2152.
Crossref
Crossref
Can Zhao, Nan Zheng, Fen Yang, Shu‐Yan Han & Ping‐Ping Li. (2019) A validated high‐performance liquid chromatography–tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: Application to a pharmacokinetics study. Biomedical Chromatography 33:11.
Crossref
Crossref
Shaoxing Guan, Xi Chen, Fei Wang, Shuang Xin, Wei Feng, Xia Zhu, Shu Liu, Wei Zhuang, Shan Zhou, Min Huang, Xueding Wang & Li Zhang. (2019) Development and validation of a sensitive LC–MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis 172, pages 364-371.
Crossref
Crossref
Cristina Pérez-Ramírez, Marisa Cañadas-Garre, Miguel Ángel Molina, José Cabeza Barrera & María José Faus-Dáder. (2019) Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients. Mutation Research/Reviews in Mutation Research 781, pages 63-70.
Crossref
Crossref
Toshio Kawata, Mitsuo Higashimori, Yohji Itoh, Helen Tomkinson, Martin G. Johnson, Weifeng Tang, Fredrik Nyberg, Haiyi Jiang & Yusuke Tanigawara. (2019) Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 83:5, pages 849-858.
Crossref
Crossref
Yi-Kun Wang, Xue-Rong Xiao, Kang-Ping Xu & Fei Li. (2018) Metabolic profiling of the anti-tumor drug regorafenib in mice. Journal of Pharmaceutical and Biomedical Analysis 159, pages 524-535.
Crossref
Crossref
Kwon-Yeon Weon, Min Gi Kim, Soyoung Shin, Tae Hwan Kim, Sang Hoon Joo, Eunsook Ma, Seok Won Jeong, Sun Dong Yoo, Yu Seok Youn & Beom Soo Shin. (2018) Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats. Chinese Journal of Integrative Medicine 24:6, pages 460-466.
Crossref
Crossref
Hye-Rim Kim, Jong-Woo Jeong, Sang Hoon Joo & Tae-Sung Koo. (2017) Effects of Angelica gigas extract on the oral pharmacokinetics of gefitinib in rats. Journal of Pharmaceutical Investigation 48:3, pages 295-300.
Crossref
Crossref
Dan-Dan Wang, Yong Liu, Na Li, Yi Zhang, Qiang Jin, Da-Cheng Hao, Hai-Long Piao, Zi-Ru Dai, Guang-Bo Ge & Ling Yang. (2017) Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells. Toxicology in Vitro 44, pages 36-43.
Crossref
Crossref
Meghan M. Cromie, Zhongwei Liu & Weimin Gao. (2017) Epigallocatechin‐3‐gallate augments the therapeutic effects of benzo[a]pyrene‐mediated lung carcinogenesis. BioFactors 43:4, pages 529-539.
Crossref
Crossref
Y Ma, S Xin, M Huang, Y Yang, C Zhu, H Zhao, Y Zhang, L Chen, Y Zhao, J Li, W Zhuang, X Zhu, L Zhang & X Wang. (2016) Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. The Pharmacogenomics Journal 17:4, pages 325-330.
Crossref
Crossref
Hiroyuki Kobayashi, Kazuhiro Sato, Takenori Niioka, Masahide Takeda, Yuji Okuda, Mariko Asano, Hiroshi Ito & Masatomo Miura. (2016) Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Medical Oncology 33:6.
Crossref
Crossref
Jingjing Wang, Yanlin Wu, Mei Dong, Xiaohui He, Ziping Wang, Junling Li & Yan Wang. (2016) Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. Anti-Cancer Drugs 27:3, pages 245-250.
Crossref
Crossref
Takashi Hirose, Ken-ichi Fujita, Sojiro Kusumoto, Yasunari Oki, Yasunori Murata, Tomohide Sugiyama, Hiroo Ishida, Takao Shirai, Masanao Nakashima, Toshimitsu Yamaoka, Kentaro Okuda, Tohru Ohmori & Yasutsuna Sasaki. (2016) Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer 93, pages 69-76.
Crossref
Crossref
Nan Zheng, Can Zhao, Xi-Ran He, Shan-Tong Jiang, Shu-Yan Han, Guo-Bing Xu & Ping-Ping Li. (2016) Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC–MS/MS and its application to a pharmacokinetics study. Journal of Chromatography B 1011, pages 215-222.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
584
601
.
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
518
520
.
Eri Sugiyama, Shigeki Umemura, Shogo Nomura, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Masahiro Tsuboi, Yuichiro Ohe & Koichi Goto. (2015) Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 90:2, pages 307-313.
Crossref
Crossref
Xing Liu, Yuanfu Lu, Xinfu Guan, Bingning Dong, Hemantkumar Chavan, Jin Wang, Yiqing Zhang, Partha Krishnamurthy & Feng Li. (2015) Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochemical Pharmacology 97:1, pages 111-121.
Crossref
Crossref
Hiroyuki Kobayashi, Kazuhiro Sato, Takenori Niioka, Hajime Miura, Hiroshi Ito & Masatomo Miura. (2015) Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer 16:4, pages 274-281.
Crossref
Crossref
Kuan-Li Wu, Ming-Ju Tsai, Chih-Jen Yang, Wei-An Chang, Jen-Yu Hung, Chun-Ju Yen, Chi-Hsiang Shen, Tzu-Yu Kuo, Jui-Ying Lee, Shah-Hwa Chou, Ta-Chih Liu, Inn-Wen Chong & Ming-Shyan Huang. (2015) Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer 88:2, pages 187-194.
Crossref
Crossref
Hanaka Mimura, Kaoru Kobayashi, Linxiaoqing Xu, Mari Hashimoto, Yoko Ejiri, Masaya Hosoda & Kan Chiba. (2015) Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4. Drug Metabolism and Pharmacokinetics 30:1, pages 105-110.
Crossref
Crossref
Nobuhiro Asai, Yoshihiro Ohkuni, Etsuro Yamaguchi & Norihiro Kaneko. (2015) Successful treatment of non-small cell lung cancer with gefitinib after erlotinib-induced severe eyelid erosion. Journal of Cancer Research and Therapeutics 11:3, pages 653.
Crossref
Crossref
Balraj Mittal, Sonam Tulsyan, Surendra Kumar, Rama Devi Mittal & Gaurav Agarwal. 2015.
77
139
.
Mafalda Videira, Rita Leones Reis & Maria Alexandra Brito. (2014) Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846:2, pages 312-325.
Crossref
Crossref
Zhi‐Xin Wang, Jiazhi Sun, Caitlin E. Howell, Qing‐Yu Zhou, Zhi‐Xu He, Tianxin Yang, Helen Chew, Wei Duan, Zhi‐Wei Zhou, Jagat R. Kanwar & Shu‐Feng Zhou. (2014) Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundamental & Clinical Pharmacology 28:5, pages 551-582.
Crossref
Crossref
Solange Peters, Stefan Zimmermann & Alex A. Adjei. (2014) Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions. Cancer Treatment Reviews 40:8, pages 917-926.
Crossref
Crossref
Shu-Yan Han, Hai-Yu Zhao, Ning Zhou, Fei Zhou & Ping-Ping Li. (2014) Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes. Journal of Ethnopharmacology 151:1, pages 210-217.
Crossref
Crossref
Audrey Thomas-Schoemann, Benoit Blanchet, Christophe Bardin, Gaëlle Noé, Pascaline Boudou-Rouquette, Michel Vidal & François Goldwasser. (2014) Drug interactions with solid tumour-targeted therapies. Critical Reviews in Oncology/Hematology 89:1, pages 179-196.
Crossref
Crossref
Michael Tagen & Clinton F. Stewart. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
625
659
.
Jian Meng. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
5
.
Takayuki Takimoto, Takashi Kijima, Yasushi Otani, Shinpei Nonen, Yoshinobu Namba, Masahide Mori, Soichiro Yokota, Seigo Minami, Kiyoshi Komuta, Junji Uchida, Fumio Imamura, Mitsugi Furukawa, Naotoshi Tsuruta, Yasushi Fujio, Junichi Azuma, Isao Tachibana & Atsushi Kumanogoh. (2013) Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity. Clinical Lung Cancer 14:5, pages 502-507.
Crossref
Crossref
Sukhmani K. Padda, Laveena Chhatwani, Lisa Zhou, Charlotte D. Jacobs, Arturo Lopez-Anaya & Heather A. Wakelee. (2013) Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer. Anti-Cancer Drugs 24:7, pages 731-735.
Crossref
Crossref
Eunyoung Kim, Hankyong Kim, Kweehyun Suh, Sechang Kwon, Gwansun Lee, Na Hyun Park & Jongki Hong. (2013) Metabolite identification of a new tyrosine kinase inhibitor, HM781‐36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 27:11, pages 1183-1195.
Crossref
Crossref
Hidemi Kiyota, Isamu Okamoto, Masayuki Takeda, Haruko Daga, Tateaki Naito, Masaki Miyazaki, Hideaki Okada, Hidetoshi Hayashi, Kaoru Tanaka, Masaaki Terashima, Koichi Azuma, Haruyasu Murakami, Koji Takeda, Nobuyuki Yamamoto & Kazuhiko Nakagawa. (2013) Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. Cancer Chemotherapy and Pharmacology 71:4, pages 859-865.
Crossref
Crossref
Antonio Rossi, Dario Cova, Silvana Leo & Lazzaro Repetto. 2013. Management of Lung Cancer in Older People. Management of Lung Cancer in Older People
65
87
.
Tomohiro Suzumura, Tatsuo Kimura, Shinzoh Kudoh, Kanako Umekawa, Misato Nagata, Kuniomi Matsuura, Hidenori Tanaka, Shigeki Mitsuoka, Naruo Yoshimura, Yukimi Kira, Toshiyuki Nakai & Kazuto Hirata. (2012) Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC Cancer 12:1.
Crossref
Crossref
Hua Lv, Fan Wang, M. V. Ramana Reddy, Qingyu Zhou, Xiaoping Zhang, E. Premkumar Reddy & James M. Gallo. (2012) Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Investigational New Drugs 30:6, pages 2263-2273.
Crossref
Crossref
SEIICHIRO SAKAO & KOICHIRO TATSUMI. (2012) Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors. Oncology Letters 4:5, pages 865-867.
Crossref
Crossref
Valérie Campagna-Slater, Joshua Pottel, Eric Therrien, Louis-David Cantin & Nicolas Moitessier. (2012) Development of a Computational Tool to Rival Experts in the Prediction of Sites of Metabolism of Xenobiotics by P450s. Journal of Chemical Information and Modeling 52:9, pages 2471-2483.
Crossref
Crossref
Ling-Zhi Wang, Rina Yue-Ling Ong, Tan-Min Chin, Win-Lwin Thuya, Seow-Ching Wan, Andrea Li-Ann Wong, Sui-Yung Chan, Paul C. Ho & Boon-Cher Goh. (2012) Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 61, pages 86-92.
Crossref
Crossref
Katsumi Nakatomi, Yoichi Nakamura, Iida Tetsuya & Shigeru Kohno. (2011) Treatment with gefitinib after erlotinib-induced liver injury: a case report. Journal of Medical Case Reports 5:1.
Crossref
Crossref
Jiri Horak, Jeff White, Adrian L. Harris, Mark Verrill, James Carmichael, Alison Holt, Mireille Cantarini, Merran Macpherson, Alan Swaisland, Helen Swaisland & Chris Twelves. (2011) The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology 68:6, pages 1485-1495.
Crossref
Crossref
Naoko Yamamoto, Masashi Honma & Hiroshi Suzuki. (2011) Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders. Molecular Pharmacology 80:3, pages 466-475.
Crossref
Crossref
Takashi Kijima, Tomohito Shimizu, Shinpei Nonen, Mitsugi Furukawa, Yasushi Otani, Toshiyuki Minami, Ryo Takahashi, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Sho Goya, Yasushi Fujio, Junichi Azuma, Isao Tachibana & Ichiro Kawase. (2011) Safe and Successful Treatment With Erlotinib After Gefitinib-Induced Hepatotoxicity: Difference in Metabolism As a Possible Mechanism. Journal of Clinical Oncology 29:19, pages e588-e590.
Crossref
Crossref
Matthias Scheffler, Paola Di Gion, Oxana Doroshyenko, Jürgen Wolf & Uwe Fuhr. (2011) Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics 50:6, pages 371-403.
Crossref
Crossref
Julie Scholler & Dominique Levêque. (2011) Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. Oncology Reviews 5:2, pages 77-92.
Crossref
Crossref
Masayuki Takeda, Isamu Okamoto, Masahiro Fukuoka & Kazuhiko Nakagawa. (2010) Successful Treatment With Erlotinib After Gefitinib-Related Severe Hepatotoxicity. Journal of Clinical Oncology 28:17, pages e273-e274.
Crossref
Crossref
Akihiro Hisaka, Yoshiyuki Ohno, Takehito Yamamoto & Hiroshi Suzuki. (2010) Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacology & Therapeutics 125:2, pages 230-248.
Crossref
Crossref
Shu-Feng Zhou. 2010. Supportive Cancer Care with Chinese Medicine. Supportive Cancer Care with Chinese Medicine
293
340
.
Robert A. B. van Waterschoot, Rogier W. Rooswinkel, Rolf W. Sparidans, Antonius E. van Herwaarden, Jos H. Beijnen & Alfred H. Schinkel. (2009) Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam. Drug Metabolism and Disposition 37:12, pages 2305-2313.
Crossref
Crossref
Yuri Rukazenkov, Georgina Speake, Gayle Marshall, Judith Anderton, Barry R. Davies, Robert W. Wilkinson, D. Mark Hickinson & Alan Swaisland. (2009) Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anti-Cancer Drugs 20:10, pages 856-866.
Crossref
Crossref
Xiaohai Li, Theodore M. Kamenecka & Michael D. Cameron. (2009) Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities. Chemical Research in Toxicology 22:10, pages 1736-1742.
Crossref
Crossref
Stephanie Chhun, Celine Verstuyft, Nathalie Rizzo‐Padoin, Guy Simoneau, Laurent Becquemont, Ilana Peretti, Alan Swaisland, Robert Wortelboer, Jean Francois Bergmann & Stephane Mouly. (2009)
Gefitinib–phenytoin interaction is not correlated with the
14
C‐erythromycin breath test in healthy male volunteers
. British Journal of Clinical Pharmacology 68:2, pages 226-237.
Crossref
Crossref
Yoichi NaitoKoichi Goto. (2009) Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. Clinical Medicine. Therapeutics 1, pages CMT.S2122.
Crossref
Crossref
Mariano Monzo, Alfons Navarro, Gerardo Ferrer & Rosa Artells. (2008) Pharmacogenomics: a tool for improving cancer chemotherapy. Clinical and Translational Oncology 10:10, pages 628-637.
Crossref
Crossref
Zhongmin Guan, Xiaoyan Chen, Yinxiang Wang & Dafang Zhong. (2008) Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 22:14, pages 2176-2184.
Crossref
Crossref
Mireille V. Cantarini, Chris J. Bailey, Barbara Collins & Robert P. Smith. (2007) The relative bioavailability of gefitinib administered by granular formulation. Cancer Chemotherapy and Pharmacology 62:2, pages 203-208.
Crossref
Crossref
Ron H.N. van Schaik. (2008) CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resistance Updates 11:3, pages 77-98.
Crossref
Crossref
Bertrand Rochat, Aurélie Fayet, Nicolas Widmer, Sabine L. Lahrichi, Benoît Pesse, Laurent A. Décosterd & Jérôme Biollaz. (2008) Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography–mass spectrometry. Journal of Mass Spectrometry 43:6, pages 736-752.
Crossref
Crossref
Michael D. Prados, W. K. A. Yung, Patrick Y. Wen, Larry Junck, Timothy Cloughesy, Karen Fink, Susan Chang, H. Ian Robins, Janet Dancey & John Kuhn. (2007) Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemotherapy and Pharmacology 61:6, pages 1059-1067.
Crossref
Crossref
Kedar Purnapatre, Sunil K. Khattar & Kulvinder Singh Saini. (2008) Cytochrome P450s in the development of target-based anticancer drugs. Cancer Letters 259:1, pages 1-15.
Crossref
Crossref
Andreas H. Groll & Thomas J. Walsh. 2008. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
316
335
.
Jeffrey A. Meyerhardt, Jeffrey W. Clark, Jeffrey G. Supko, Joseph P. Eder, Shuji Ogino, Clinton F. Stewart, Ferdinando D’Amato, Janet Dancey, Peter C. Enzinger, Andrew X. Zhu, David P. Ryan, Craig C. Earle, Robert J. Mayer, Ann Michelini, Kate Kinsella & Charles S. Fuchs. (2007) Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 60:5, pages 661-670.
Crossref
Crossref
Jing Li, Ming Zhao, Ping He, Manuel Hidalgo & Sharyn D. Baker. (2007) Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clinical Cancer Research 13:12, pages 3731-3737.
Crossref
Crossref
Tom Mikkelsen, Richard Lush, Stuart A. Grossman, Kathryn A. Carson, Joy D. Fisher, Jane B. Alavi & Steve Rosenfeld. (2006) Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Investigational New Drugs 25:3, pages 259-263.
Crossref
Crossref
Alex A. Adjei, Julian R. Molina, Sumithra J. Mandrekar, Randolph Marks, Joel R. Reid, Gary Croghan, Lorelei J. Hanson, James R. Jett, Chenghua Xia, Chetan Lathia & Ronit Simantov. (2007) Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer. Clinical Cancer Research 13:9, pages 2684-2691.
Crossref
Crossref
I. Chau, D. Cunningham, T. Hickish, A. Massey, L. Higgins, R. Osborne, N. Botwood & A. Swaisland. (2007) Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study. Annals of Oncology 18:4, pages 730-737.
Crossref
Crossref
Bernard Testa & Stefanie D. Krämer. (2007) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 4:3, pages 257-405.
Crossref
Crossref
Matthew G. Fury, David B. Solit, Yungpo Bernard Su, Neal Rosen, F. M. Sirotnak, Robert P. Smith, Christopher G. Azzoli, Jorge E. Gomez, Vincent A. Miller, Mark G. Kris, Barbara A. Pizzo, Roxanne Henry, David G. Pfister & Naiyer A. Rizvi. (2006) A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 59:4, pages 467-475.
Crossref
Crossref
G. Toffoli, E. De Mattia, E. Cecchin, P. Biason, S. Masier & G. Corona. (2018) Pharmacology of Epidermal Growth Factor Inhibitors. The International Journal of Biological Markers 22:1_suppl4, pages 24-39.
Crossref
Crossref
Jing Li, Mats O. Karlsson, Julie Brahmer, Avery Spitz, Ming Zhao, Manuel Hidalgo & Sharyn D. Baker. (2006) CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors. JNCI: Journal of the National Cancer Institute 98:23, pages 1714-1723.
Crossref
Crossref
Shellie M. Callahan, Michael P. Boquet, Xin Ming, Lane J. Brunner & Maria A. Croyle. (2006) Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. The Journal of Gene Medicine 8:5, pages 566-576.
Crossref
Crossref
Paul Frohna, Jianfeng Lu, Steve Eppler, Marta Hamilton, Julie Wolf, Ashok Rakhit, Jie Ling, Saraswati R. Kenkare‐Mitra & Bert L. Lum. (2013) Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects. The Journal of Clinical Pharmacology 46:3, pages 282-290.
Crossref
Crossref
N. Hariparsad, R.S. Sane, S.C. Strom & P.B. Desai. (2006) In vitro methods in human drug biotransformation research: Implications for cancer chemotherapy. Toxicology in Vitro 20:2, pages 135-153.
Crossref
Crossref
Helen C Swaisland, Mireille V Cantarini, Rainard Fuhr & Alison Holt. (2006) Exploring the Relationship Between Expression of Cytochrome P450??Enzymes and Gefitinib Pharmacokinetics. Clinical Pharmacokinetics 45:6, pages 633-644.
Crossref
Crossref
Ron H.J. Mathijssen & Ron H.N. van Schaik. (2006) Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment. European Journal of Cancer 42:2, pages 141-148.
Crossref
Crossref
Ron H. N. van Schaik. (2005) Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Investigational New Drugs 23:6, pages 513-522.
Crossref
Crossref
Timothy Kuo & George A. Fisher. (2005) Current Status of Small-Molecule Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor in Colorectal Cancer. Clinical Colorectal Cancer 5, pages S62-S70.
Crossref
Crossref
David McKillop, Elizabeth A. Partridge, John V. Kemp, Mike P. Spence, Jane Kendrew, Sharon Barnett, Phillippa G. Wood, Petrina B. Giles, Andrew B. Patterson, Francis Bichat, Nicolas Guilbaud & Trevor C. Stephens. (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 4:4, pages 641-649.
Crossref
Crossref